الفهرس | Only 14 pages are availabe for public view |
Abstract During the past decade many factors such as age, systolic blood pressure, hyperphosphatemia and fibroblast growth factor 23 (FGF23) have been addressed as causes of vascular calcification and hence of increasing morbidity and mortality among haemodialysis patients. FGF23, a phosphaturic factor produced by osteoblasts has emerged as a major regulator of mineral metabolism in health and disease. Under physiological conditions, it acts as a circulating phosphaturic factor through suppression of proximal tubular Na / Pi-2c co transporters. FGF23 together with its cofactor Klotho have been found to be expressed and FGF23 to be elevated in patients on haemodialysis |